A MULTICENTER REGISTRY ANALYSIS
The HeartMate 3™ LVAD was originally designed for use in adults with heart failure. This study, published in the Journal of Heart and Lung Transplantation on February, 13th 2020, sought to assess the use of the HeartMate 3 VAD in children and adults with congenital heart disease (CHD): “Early experience with the HeartMate 3 continuous-flow ventricular assist device in pediatric patients and patients with congenital heart disease: A multicenter registry analysis.”
Looking at the use of the HeartMate 3™ in 35 patients with heart failure at 9 ACTION centers between December 2017 and September 2019, researchers found low incidence of mortality and adverse events in pediatric patients with congenital heart disease (CHD). While the HeartMate 3 VAD is FDA approved used for bridge-to-transplant and Destination Therapy in adults, this study demonstrates that the HeartMate 3 VAD may be appropriate for older children and adults with CHD. ACTION is proud that the real-world data we’ve collected has led to the FDA expanding Abbott’s HeartMate 3™ LVAD labeling to include children. We’re hopeful that increased regulatory approval and support for devices for use in pediatric and CHD heart failure will propel our field forward.
Matthew O’Connor of Children’s Hospital of Philadelphia, Angela Lorts of Cincinnati Children’s Hospital Medical Center, Anna Joong of Lurie Children’s Hospital of Chicago, Deipanjan Nandi of Nationwide Children’s Hospital, David Peng of C.S. Mott Children’s Hospital, David Rosenthal at Stanford Children’s Health, David Sutcliffe of Children’s Health Dallas / UT Southwestern, Christina VanderPluym of Boston Children’s Hospital, Farhan Zafar of Cincinnati Children’s Hospital Medical Center, and David Morales of Cincinnati Children’s Hospital Medical Center.
CITATION
O’Connor MJ, Lorts A, Davies RR, et al. Early experience with the HeartMate 3 continuous-flow ventricular assist device in pediatric patients and patients with congenital heart disease: A multicenter registry analysis. J Heart Lung Transplant. 2020;39(6):573-579. doi:10.1016/j.healun.2020.02.007
